A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

ClinicalTrials.gov ID: NCT06515613

Public ClinicalTrials.gov record NCT06515613. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 16, 2026, 1:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, First in Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody , in participants with platinum-refractory/resistant ovarian cancer (PRROC) and other advanced CLDN6-positive solid tumors (i.e., testicular and endometrial).

Study identification

NCT ID: NCT06515613
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Context Therapeutics Inc.; Industry
Enrollment: 156 participants

Conditions and interventions

Conditions

Interventions

CTIM-76 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 9, 2024
Primary completion: May 30, 2028
Completion: Dec 30, 2028
Last update posted: Sep 2, 2026

2024 – 2028

United States locations

U.S. sites: 14
U.S. states: 14
U.S. cities: 14

Facility	City	State	ZIP	Site status
University of Arkansas Winthrop P. Rockefeller Cancer Institute	Little Rock	Arkansas	72205	Recruiting
Precision NextGen Oncology & Research Center	Beverly Hills	California	90212	Withdrawn
SCRI at Denver Health	Denver	Colorado	80218	Recruiting
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
University of Nebraska Medical	Omaha	Nebraska	68198	Recruiting
John Theurer Cancer Center	Hackensack	New Jersey	07601	Terminated
Memorial Sloan Kettering Cancer Center	New York	New York	10021	Recruiting
Duke Cancer Institute	Durham	North Carolina	27710	Recruiting
Gabrail Cancer Center	Canton	Ohio	44718	Withdrawn
Providence Cancer Institute of Oregon	Portland	Oregon	97213	Recruiting
Fox Chase Cancer Center	Philadelphia	Pennsylvania	19111	Withdrawn
Women & Infants Hospital of Rhode Island	Providence	Rhode Island	02905	Recruiting
Vanderbilt-Ingram Cancer Center	Nashville	Tennessee	37232	Recruiting
SCRI at Mary Crowley	Dallas	Texas	75230	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06515613, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 2, 2026 · Synced Sep 16, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06515613 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →